<DOC>
	<DOCNO>NCT02683928</DOCNO>
	<brief_summary>The purpose study determine effect GBR 830 biomarkers AD/ eczema enable study indication .</brief_summary>
	<brief_title>To Assess Safety Activity GBR 830 , Compared Placebo , Adult Patients With Moderate-to-severe Atopic Dermatitis ( AD )</brief_title>
	<detailed_description>Approximately 40 patient meet eligibility criterion undergo baseline assessment randomize receive GBR 830 placebo . Safety tolerability GBR 830 evaluate patient AD/eczema .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Male female , 18 year old Moderate severe atopic dermatitis present great 1 year screen BSA â‰¥10 % . Treatment systemic corticosteroid within 4 week randomization , topical steroids/tacrolimus or/pimecrolimus within 1 week randomization ( except emollient , mild steroid ( class 6 7 ) Any celldepleting agent include limited rituximab : within 6 month prior baseline visit lymphocyte CD 19+ lymphocyte count return normal , whichever longer . Other biologics : within 5 halflives 8 week prior baseline visit , whichever longer . Allergen immunotherapy within 6 month baseline visit . Patient history serious local infection systemic infection Patient history current evidence disease tuberculosis , malignant disease , inflammatory autoimmune disease HIV Hepatitis B C positive . Pregnant breastfeed woman woman plan become pregnant breastfeed study unwilling use adequate birth control , reproductive potential sexually active</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>